IT1401253B1 - Uso del sulodexide per la riduzione delle metalloproteinasi di matrice. - Google Patents

Uso del sulodexide per la riduzione delle metalloproteinasi di matrice.

Info

Publication number
IT1401253B1
IT1401253B1 ITBO2010A000250A ITBO20100250A IT1401253B1 IT 1401253 B1 IT1401253 B1 IT 1401253B1 IT BO2010A000250 A ITBO2010A000250 A IT BO2010A000250A IT BO20100250 A ITBO20100250 A IT BO20100250A IT 1401253 B1 IT1401253 B1 IT 1401253B1
Authority
IT
Italy
Prior art keywords
sulodexide
reduction
matrix metalloproteinase
metalloproteinase
matrix
Prior art date
Application number
ITBO2010A000250A
Other languages
English (en)
Inventor
Giuseppe Claudio Viscomi
Ferdinando Mannello
Original Assignee
Uni Degli Studi Carlo Bo Urbino
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43063923&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IT1401253(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Uni Degli Studi Carlo Bo Urbino, Alfa Wassermann Spa filed Critical Uni Degli Studi Carlo Bo Urbino
Priority to ITBO2010A000250A priority Critical patent/IT1401253B1/it
Priority to PL13161007T priority patent/PL2609925T3/pl
Priority to KR1020127027513A priority patent/KR101739757B1/ko
Priority to PCT/IB2011/051726 priority patent/WO2011132161A2/en
Priority to EP11723652.1A priority patent/EP2560662B1/en
Priority to ES11723652.1T priority patent/ES2628582T3/es
Priority to US13/642,510 priority patent/US8987231B2/en
Priority to PT117236521T priority patent/PT2560662T/pt
Priority to ES13161007.3T priority patent/ES2694587T3/es
Priority to EP13161007.3A priority patent/EP2609925B1/en
Priority to RU2012142256/15A priority patent/RU2557996C2/ru
Priority to KR1020167013025A priority patent/KR20160060164A/ko
Priority to CN201180020126XA priority patent/CN102883728A/zh
Priority to PT13161007T priority patent/PT2609925T/pt
Priority to PL11723652T priority patent/PL2560662T3/pl
Priority to MX2012012285A priority patent/MX339537B/es
Publication of ITBO20100250A1 publication Critical patent/ITBO20100250A1/it
Publication of IT1401253B1 publication Critical patent/IT1401253B1/it
Application granted granted Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dispersion Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ITBO2010A000250A 2010-04-23 2010-04-23 Uso del sulodexide per la riduzione delle metalloproteinasi di matrice. IT1401253B1 (it)

Priority Applications (16)

Application Number Priority Date Filing Date Title
ITBO2010A000250A IT1401253B1 (it) 2010-04-23 2010-04-23 Uso del sulodexide per la riduzione delle metalloproteinasi di matrice.
ES13161007.3T ES2694587T3 (es) 2010-04-23 2011-04-20 Sulfato de dermatán para uso en el tratamiento de patologías en las que están involucradas metaloproteinasas
RU2012142256/15A RU2557996C2 (ru) 2010-04-23 2011-04-20 Сулодексид для применения в лечении патологий, в которые вовлечены металлопротеиназы
PCT/IB2011/051726 WO2011132161A2 (en) 2010-04-23 2011-04-20 Sulodexide for use in the treatment of pathologies wherein metalloproteinases are involved
EP11723652.1A EP2560662B1 (en) 2010-04-23 2011-04-20 Sulodexide for use in the treatment of pathologies wherein metalloproteinases are involved
ES11723652.1T ES2628582T3 (es) 2010-04-23 2011-04-20 Sulodexida para uso en el tratamiento de patologías en las que están involucradas metaloproteinasas
US13/642,510 US8987231B2 (en) 2010-04-23 2011-04-20 Sulodexide for use in the treatment of pathologies wherein metalloproteinases are involved
PT117236521T PT2560662T (pt) 2010-04-23 2011-04-20 Sulodexide para a utilização no tratamento de patologias nas quais as metaloproteínases estão envolvidas
PL13161007T PL2609925T3 (pl) 2010-04-23 2011-04-20 Siarczan dermatanu do zastosowania w leczeniu patologii, w których uczestniczą metaloproteinazy
EP13161007.3A EP2609925B1 (en) 2010-04-23 2011-04-20 Dermatan sulfate for use in the treatment of pathologies wherein metalloproteinases are involved
KR1020127027513A KR101739757B1 (ko) 2010-04-23 2011-04-20 메탈로프로테이나제가 연관된 병리 치료에 사용하기 위한 설로덱사이드
KR1020167013025A KR20160060164A (ko) 2010-04-23 2011-04-20 메탈로프로테이나제가 연관된 병리 치료에 사용하기 위한 설로덱사이드
CN201180020126XA CN102883728A (zh) 2010-04-23 2011-04-20 用于治疗其中涉及金属蛋白酶的病变的舒洛地昔
PT13161007T PT2609925T (pt) 2010-04-23 2011-04-20 Sulfato de dermatano para utilização no tratamento de patologias em que estão envolvidos metaloproteinases
PL11723652T PL2560662T3 (pl) 2010-04-23 2011-04-20 Sulodeksyd do zastosowania w leczeniu patologii, w których uczestniczą metaloproteinazy
MX2012012285A MX339537B (es) 2010-04-23 2011-04-20 Sulodexide para uso en el tratamiento de patologias en donde estan involucradas las metalo proteinasas.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITBO2010A000250A IT1401253B1 (it) 2010-04-23 2010-04-23 Uso del sulodexide per la riduzione delle metalloproteinasi di matrice.

Publications (2)

Publication Number Publication Date
ITBO20100250A1 ITBO20100250A1 (it) 2011-10-24
IT1401253B1 true IT1401253B1 (it) 2013-07-18

Family

ID=43063923

Family Applications (1)

Application Number Title Priority Date Filing Date
ITBO2010A000250A IT1401253B1 (it) 2010-04-23 2010-04-23 Uso del sulodexide per la riduzione delle metalloproteinasi di matrice.

Country Status (11)

Country Link
US (1) US8987231B2 (it)
EP (2) EP2560662B1 (it)
KR (2) KR101739757B1 (it)
CN (1) CN102883728A (it)
ES (2) ES2694587T3 (it)
IT (1) IT1401253B1 (it)
MX (1) MX339537B (it)
PL (2) PL2609925T3 (it)
PT (2) PT2609925T (it)
RU (1) RU2557996C2 (it)
WO (1) WO2011132161A2 (it)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
AU2014339000B2 (en) * 2013-10-22 2017-05-18 Cell Receptor AG Sulfated polysaccharides for use in the treatment of cancer
CN104398533B (zh) * 2014-11-26 2017-03-08 山东辰中生物制药有限公司 舒洛地特的生产方法
RU2667650C1 (ru) * 2017-12-15 2018-09-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ лечения и профилактики острого тромбоза геморроидальных узлов

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2426586A1 (de) 1973-06-14 1975-01-09 Opocrin Srl Verfahren zur herstellung von glukuronil-glukosamin-glykan-sulfaten mit antilipaemischer wirkung
US4705798A (en) 1985-09-27 1987-11-10 University Of Iowa Research Foundation Phenylephrine prodrug useful as mydriatic agent
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
IT1242604B (it) * 1990-11-13 1994-05-16 Alfa Wassermann Spa Sali di glicosaminoglicani con esteri di aminoacidi, loro preparazione e formulazioni farmaceutiche che li contengono.
IT1245907B (it) * 1991-05-17 1994-10-25 Alfa Wassermann Spa Uso dei glicosaminoglicani nel trattamento della nefropatia diabetica e della neuropatia diabetica.
GB9215665D0 (en) 1992-07-23 1992-09-09 British Bio Technology Compounds
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
CA2150552C (en) 1993-09-30 1999-12-21 Akikazu Takada Antithrombotic
IT1274351B (it) 1994-10-06 1997-07-17 Alfa Wassermann Spa Uso di alcuni glicosaminoglicani nella dialisi peritoneale.
EA003294B1 (ru) 1995-12-08 2003-04-24 Агурон Фармасьютикалс, Инк. Ингибиторы металлопротеиназы, фармацевтические композиции, их содержащие, и их фармацевтические применения
IT1285546B1 (it) * 1996-01-16 1998-06-18 Alfa Wassermann Spa Uso del dermatano solfato a basso peso molecolare e delle specialita' medicinali che lo contengono nella terapia e nella prevenzione della
IT1299969B1 (it) * 1998-04-15 2000-04-04 Alfa Wassermann Spa Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della retinopatia diabetica.
DE69833822D1 (de) 1998-10-01 2006-05-11 Giovanni Gambaro Substanzen zur Vorbeugung von krankhafter TGF-beta Überexpression und Methoden derer Ermittlung
US20040009952A1 (en) 1998-10-19 2004-01-15 Giovanni Gambaro TGF-beta gene overexpression preventing substances for the treatment of disorders connected with pathological overexpression of TGF-beta
IL127896A0 (en) 1998-12-31 1999-10-28 Gail Laster A novel treatment for preeclampsia and related diseases
US20090325876A1 (en) * 2004-09-29 2009-12-31 Saul Yedgar Use of lipid conjugates in the treatment of diseases associated with vasculature
US7259152B2 (en) 2000-06-07 2007-08-21 Alfa Wasserman, Inc. Methods and compositions using sulodexide for the treatment of diabetic nephropathy
ATE290874T1 (de) 2000-12-16 2005-04-15 Aventis Pharma Gmbh Verwendung von niedermolekularen heparin zur behandlung von osteoarthrose
FR2864087B1 (fr) 2003-12-19 2006-01-27 Aventis Pharma Sa Derives carboxy-reduits du dermatan sulfate, leur preparation, leur application comme medicament et les compositions pharmaceutiques les renfermant
KR100808131B1 (ko) * 2006-06-22 2008-02-29 부경대학교 산학협력단 인간 섬유육종 세포에서 메트릭스 메탈로프로테이나제-9의발현을 억제시키는 카복실화 키토올리고사카라이드 화합물및 이를 함유한 메트릭스 메탈로프로테이나제-9 억제제
CN101632686A (zh) * 2008-04-04 2010-01-27 马斯特里赫特大学 糖胺聚糖用于修复糖萼的用途
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity

Also Published As

Publication number Publication date
US20130045946A1 (en) 2013-02-21
CN102883728A (zh) 2013-01-16
KR20160060164A (ko) 2016-05-27
EP2609925A3 (en) 2013-09-04
US8987231B2 (en) 2015-03-24
PT2560662T (pt) 2017-07-10
EP2609925B1 (en) 2018-10-17
PL2609925T3 (pl) 2019-02-28
ES2628582T3 (es) 2017-08-03
KR101739757B1 (ko) 2017-05-25
KR20130072199A (ko) 2013-07-01
EP2609925A2 (en) 2013-07-03
MX2012012285A (es) 2012-11-23
EP2560662A2 (en) 2013-02-27
RU2012142256A (ru) 2014-05-27
WO2011132161A3 (en) 2012-03-08
RU2557996C2 (ru) 2015-07-27
PT2609925T (pt) 2018-11-22
ITBO20100250A1 (it) 2011-10-24
ES2694587T3 (es) 2018-12-21
MX339537B (es) 2016-05-30
PL2560662T3 (pl) 2017-09-29
EP2560662B1 (en) 2017-06-07
WO2011132161A2 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
EP4421486C0 (en) ULTRASONIC MATRIX INSPECTION
DK2730215T3 (da) Dynamisk urinmonitor
BR112014031335A2 (pt) bloco de diagnóstico transacional
BR112014004908A2 (pt) aparelho para higienizar dispositivo médicos
FIC20260012I1 (fi) Molidustaatti, erityisesti molidustaattinatrium
CL2014003283A1 (es) Formulación farmacéutica.
DK2528458T3 (da) Faststof/væske-ekstraktion
EP2822173A4 (en) INDIRECT MATRIX TRANSFORMER
EP2860233A4 (en) PUNCTURE CLOSURE MEANS
EP2851931A4 (en) MICRO CHANNEL PLATE
EP2674232A4 (en) BENDER
BR112013023575A2 (pt) “derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes”
DK2931042T3 (da) Anthracyclinformuleringer
BR112014010432A2 (pt) uso médico
PL2654944T3 (pl) Katalizatory izomeryzacji
FI9797U1 (fi) Paineenkorotusyksikkö
DK2500470T3 (da) Hoved-arbejdsvogn
EP2896767A4 (en) columbarium
DK3566708T3 (da) Sporstofopløsning
CO6862122A2 (es) Sistema del panel para construcción
ITAN20120093A1 (it) Dispositivo per la decantazione del vino.
SMT201900111T1 (it) Uso di un tiazolpirimidinone per il trattamento di una malattia infiammatoria intestinale
ES1077740Y (es) Albarda para la vendimia
FR2988758B1 (fr) Columbarium
DE112013001653A5 (de) Carben-Übertragungsreagenz